ZYVERSA THERAPEUTICS, INC. Financing Cash Flow
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Financing Cash Flow of $1.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $1.00M, a 46.02% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$12.51K, a 100.48% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.86M, a 201.63% increase year-over-year.
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was -$17.72K.
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $3.69M, a 37.67% decline from fiscal 2024.
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $5.91M, a 0.73% decline from fiscal 2023.
- ZYVERSA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $5.96M.
| Period end | Net Cash Provided by (Used in) Financing Activities 0 month | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 11 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $1.00M 10-Q · filed 2026-05-13 | $987.49K derived: sum of 2 quarters · filed 2026-05-13 | $2.85M derived: sum of 3 quarters · filed 2026-05-13 | $2.83M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2025-12-31 | -$12.51K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.85M derived: sum of 2 quarters · filed 2026-03-31 | $1.83M derived: sum of 3 quarters · filed 2026-03-31 | $3.69M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $1.85M derived: sum of 2 quarters · filed 2025-11-19 | $3.70M 10-Q · filed 2025-11-19 | $6.32M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2025-06-30 | -$17.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.83M 10-Q · filed 2025-08-13 | $4.46M derived: sum of 3 quarters · filed 2026-05-13 | $5.08M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2025-03-31 | $1.85M 10-Q · filed 2026-05-13 | $4.48M derived: sum of 2 quarters · filed 2026-05-13 | $5.09M derived: sum of 3 quarters · filed 2026-05-13 | $5.09M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.24M derived: sum of 2 quarters · filed 2026-03-31 | $3.24M derived: sum of 3 quarters · filed 2026-03-31 | $5.91M 10-K · filed 2026-03-31 | $5.95M 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $617.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $617.58K derived: sum of 2 quarters · filed 2025-11-19 | $3.29M 10-Q · filed 2025-11-19 | $3.32M 10-Q · filed 2024-11-14 | $7.64M derived: sum of 4 quarters · filed 2025-11-19 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $2.67M 10-Q · filed 2025-08-13 | $7.02M derived: sum of 3 quarters · filed 2025-08-13 | $9.31M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $2.67M 10-Q · filed 2025-05-12 | $7.02M derived: sum of 2 quarters · filed 2025-05-12 | $9.31M derived: sum of 3 quarters · filed 2025-05-12 | $8.66M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $6.63M derived: sum of 2 quarters · filed 2025-03-27 | $5.99M derived: sum of 3 quarters · filed 2025-03-27 | $5.96M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.64M derived: sum of 2 quarters · filed 2024-11-14 | $1.61M 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | -$641.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$676.43K 10-Q · filed 2024-08-09 | ||||||
| 2023-03-31 | -$34.67K 10-Q · filed 2024-05-15 | |||||||
| 2022-12-12 | $1.87M 10-K · filed 2024-03-25 | |||||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $2.70M 10-Q · filed 2022-11-14 | $79.12M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $2.70M 10-Q · filed 2022-08-15 | $79.12M derived: sum of 3 quarters · filed 2022-08-15 | $79.05M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2022-03-31 | $2.70M 10-Q · filed 2022-05-13 | $79.12M derived: sum of 2 quarters · filed 2022-05-13 | $79.05M derived: sum of 3 quarters · filed 2022-11-14 | $79.81M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-12-31 | $76.42M derived: 10-K 9 month − 10-Q 6 month · filed 2022-04-15 | $76.36M derived: sum of 2 quarters · filed 2022-11-14 | $77.11M 10-K · filed 2022-04-15 | |||||
| 2021-09-30 | -$63.80K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | $686.76K 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | $750.56K 10-Q · filed 2022-08-15 | |||||||
| 2021-03-31 | $667.00 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |